We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Opioid · CPC catalog code ENDM-002
This sequence carries terminal or reporter modifications (NH2), so no molecular formula or weight is published here — the modified mass must come from the lot certificate of analysis. Residue composition and charge describe the peptide backbone only. Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of Endomorphin-2 at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Opioid class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
Endomorphin-2 sits within the Opioid research class (CPC reference ENDM-002). Opioid peptides bind μ, δ, and κ receptors — Gi/o-coupled GPCRs that inhibit adenylate cyclase, activate GIRK channels, and modulate calcium currents to produce analgesia, tolerance, and reward-circuit effects. Investigators typically incorporate Endomorphin-2 as a reference standard, tool ligand, or substrate in the assay contexts listed above. GTPγS binding, cAMP HTRF, and β-arrestin PathHunter assays.
Endomorphin-2 (CPC catalog code ENDM-002) is a synthetic opioid-receptor research peptide in the opioid category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use Endomorphin-2 as a reference standard in opioid workflows — for example, opioid-receptor binding and selectivity profiling and β-arrestin recruitment and biased-agonism studies. Human clinical evidence is not established.
No. Endomorphin-2 is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a opioid workflow, Endomorphin-2 is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. GTPγS binding, cAMP HTRF, and β-arrestin PathHunter assays.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.